Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

KOL Insight: Acute Lymphoblastic Leukaemia [2020]

Product Code:
Publication Date:
May 2020
Licence Type:
Multi-user licence

Therapy Trends KOL Insight: Acute Lymphoblastic Leukaemia

CD19 and CD22-targeting immunotherapies such as Amgen's Blincyto, Pfizer's Besponsa and Novartis' Kymriah have drastically improved outcomes for relapsed/refractory B-cell ALL and KOLs anticipate their progress into earlier treatment settings. While KOLs are convinced that new monotherapy and combination approaches will enable a reduction in the use of chemotherapy and SCT, questions remain about the optimal sequencing of treatment. US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • Why are KOLs convinced that combining Amgen's Blincyto with Pfizer's Besponsa and low-intensity chemotherapy will be advantageous?
  • In which patient subsets do KOLs see a role for Novartis' Kymriah?
  • What clinical benefits are KOLs hopeful dual targeting CAR-T therapies such as Autolus' AUTO3 will deliver?
  • Why is Takeda/Incyte's tyrosine kinase inhibitor Iclusig already being used in front line settings despite not yet being approved?
  • Where do KOLs see AbbVie/Roche's BCL-2 inhibitor Venclexta/Venclyxto succeeding in ALL?

Examples of Therapies Covered

Blincyto Besponsa
Iclusig Darzalex
Epratuzumab Kymriah
MabThera/Rituxan Gleevec/Glivec

Partial List of Participating KOLs

  • Associate Professor, Division of Hematology/Oncology/ Blood and Marrow Transplantation
    Children's Hospital of Wisconsin, Milwaukee, WI, USA.
  • Assistant Professor, Division of Hematology
    University of Washington School of Medicine, Seattle, WA, USA.
  • Medical Director of the Oncology Outpatient Clinic and an Attending Physician with the Cancer Center
    Children's Hospital of Philadelphia, PA, USA.
  • Professor and Head of Haematology, Division of Cancer and Genetics
    Cardiff University, Cardiff, UK.
  • Associate Professor
    University of Grenoble, Saint-Martin-d'Hères & Gières, France.
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner


All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved